Advice
in the absence of a submission from the holder of the marketing authorisation
paclitaxel albumin (Abraxane®) is not recommended for use within NHS Scotland.
Indication under review: in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- paclitaxel albumin (Abraxane)
- SMC ID:
- 1071/15
- Indication:
- in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 June 2015